RxDoctor Payments Data

Harpreet Johl, MD

Family Medicine · Olivehurst, CANPI 1053423202

Payments from drug & device makers

$1,075in general payments, 2019–2025

Across 48 payments — averaging $22.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$275
  • Merck$175
  • Abbott$148
  • Bayer$78
  • Exact Sciences$72
  • Novo Nordisk$61
  • plus $266 from 9 others

What the payments were for

  • Food & beverage$1,04797%
  • Education$273%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,075 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$57,986
Medicare patients
195
Services billed
438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban381$110,969
JanuviaSitagliptin Phosphate110$64,614
JardianceEmpagliflozin34$26,304
XareltoRivaroxaban71$23,538
OzempicSemaglutide13$20,883
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$20,021
Tresiba Flextouch U-200Insulin Degludec13$17,491
TradjentaLinagliptin44$14,166
TrulicityDulaglutide12$11,819
Potassium Chloride302$9,882
LinzessLinaclotide32$9,598
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$9,026
Breo ElliptaFluticasone/Vilanterol18$8,235
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$6,869
MultaqDronedarone Hcl13$5,163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$175$64,614110 claims
Boehringer IngelheimJardiance, Tradjenta$20$40,46978 claims
Johnson & JohnsonXarelto$40$23,53871 claims
Novo NordiskOzempic$61$20,88313 claims
AbbVieLinzess, Lumigan$275$12,60043 claims
Lilly USA, LLCTrulicity$15$11,81912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Olivehurst

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →